Abstract
HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in metastatic patients, as well as halving the recurrence rate and improving survival in early breast cancer. Even with these impressive results, the reality is that not all patients will benefit form this therapy, and in those who do, resistance to trastuzumab can often develop within 1 year of treatment initiation. Beyond trastuzumab therapy, a “second wave” of monoclonal antibodies and tyrosine kinase inhibitors has emerged. These drugs have variable properties including: 1) dual inhibition against EGFR and HER-2, such as lapatinib, HKI-272 and pertuzumab; 2) antiangiogenesis such as bevacizumab and pazopanib; 3) anti-mTOR action such as Temsirolimus; and 4) anti-Hsp90 such as 17-AAG. When used in combination with trastuzumab, or with cytotoxic chemotherapy, or as single agents, these new anti-HER-2 strategies bear the potential of arresting the tumorigenesis process. In this article, we present the current strategies in the treatment of breast cancer patients who overexpress HER-2, with particular focus on new tyrosine kinase inhibitors that can be used in combination with or after trastuzumab therapy.
Keywords: Breast cancer, TKI, lapatinib, HKI-272, temsirolimus, HSP-90
Anti-Cancer Agents in Medicinal Chemistry
Title: HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Volume: 8 Issue: 5
Author(s): Christian Widakowich, Phuong Dinh, Evandro de Azambuja, Ahmad Awada and Martine Piccart-Gebhart
Affiliation:
Keywords: Breast cancer, TKI, lapatinib, HKI-272, temsirolimus, HSP-90
Abstract: HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in metastatic patients, as well as halving the recurrence rate and improving survival in early breast cancer. Even with these impressive results, the reality is that not all patients will benefit form this therapy, and in those who do, resistance to trastuzumab can often develop within 1 year of treatment initiation. Beyond trastuzumab therapy, a “second wave” of monoclonal antibodies and tyrosine kinase inhibitors has emerged. These drugs have variable properties including: 1) dual inhibition against EGFR and HER-2, such as lapatinib, HKI-272 and pertuzumab; 2) antiangiogenesis such as bevacizumab and pazopanib; 3) anti-mTOR action such as Temsirolimus; and 4) anti-Hsp90 such as 17-AAG. When used in combination with trastuzumab, or with cytotoxic chemotherapy, or as single agents, these new anti-HER-2 strategies bear the potential of arresting the tumorigenesis process. In this article, we present the current strategies in the treatment of breast cancer patients who overexpress HER-2, with particular focus on new tyrosine kinase inhibitors that can be used in combination with or after trastuzumab therapy.
Export Options
About this article
Cite this article as:
Widakowich Christian, Dinh Phuong, Azambuja de Evandro, Awada Ahmad and Piccart-Gebhart Martine, HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533062
DOI https://dx.doi.org/10.2174/187152008784533062 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biotechnological Production of Statins: Metabolic Aspects and Genetic Approaches
Current Pharmaceutical Biotechnology Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology GMDR: Versatile Software for Detecting Gene-Gene and Gene-Environment Interactions Underlying Complex Traits
Current Genomics IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Radioimmunotherapy of Infection with 213Bi-Labeled Antibodies
Current Radiopharmaceuticals Adjuvant Treatment of Early Breast Cancer in the Elderly
Medicinal Chemistry New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptide Agonists and Antagonists with Potential Application in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Acoustic Radiation Force Impulse (ARFI) Imaging: A Review
Current Medical Imaging Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2)
Current Cancer Drug Targets Fecal Microbiota Transplant: Latest Addition to Arsenal against Recurrent <i>Clostridium difficile</i> Infection
Recent Advances in Anti-Infective Drug Discovery Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism